Seven Eight Capital LP Sells 8,837 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Seven Eight Capital LP reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 5.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 152,511 shares of the biopharmaceutical company’s stock after selling 8,837 shares during the period. Seven Eight Capital LP’s holdings in Amicus Therapeutics were worth $1,513,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Headlands Technologies LLC purchased a new position in Amicus Therapeutics in the second quarter valued at approximately $89,000. Sage Capital Advisors llc purchased a new stake in Amicus Therapeutics in the second quarter worth $103,000. Old Well Partners LLC bought a new stake in shares of Amicus Therapeutics in the fourth quarter valued at $180,000. EntryPoint Capital LLC lifted its position in shares of Amicus Therapeutics by 278.8% during the 1st quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 9,729 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. purchased a new position in shares of Amicus Therapeutics during the 1st quarter valued at $225,000.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total value of $77,550.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction dated Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $10.34, for a total value of $77,550.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $9,168,002.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,100 shares of company stock valued at $226,375. 2.20% of the stock is owned by corporate insiders.

Amicus Therapeutics Stock Up 0.8 %

Shares of NASDAQ:FOLD opened at $11.00 on Friday. The firm has a fifty day moving average price of $11.01 and a two-hundred day moving average price of $10.75. The company has a market cap of $3.26 billion, a price-to-earnings ratio of -22.63 and a beta of 0.69. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $126.67 million during the quarter, compared to analyst estimates of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The firm’s quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.15) earnings per share. Analysts anticipate that Amicus Therapeutics, Inc. will post -0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. Jefferies Financial Group began coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $18.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a report on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price objective for the company. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, August 16th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.